Maizel Ari

CCO Maizel Ari sold all 7,500 AXSM shares for $1.4M at $182.42, exiting full position near 52-week peak

Maizel Ari, Chief Commercial Officer, liquidated his entire 7,500-share stake in Axsome Therapeutics for $1,368,150.00 on 2026-04-22 at $182.42 per share. The sale occurred near the 52-week high of $189.10, with the stock currently trading at $182.72, down 3.4% from that peak. His cross-ticker track record shows 1 prior sell with a 100.00% well-timed rate at the 90-day mark, and his single prior trade at AXSM (a sell on 2026-01-21) also registered negative 90-day returns of -0.8%. A complete exit by a C-level executive during strong recent price momentum (the stock is up 15.1% over 30 days) merits investor attention, particularly given Axsome's unprofitable financial position (net income of $-47,229,000.00 on $170,992,000.00 quarterly revenue) despite robust 65.6% annual revenue growth. The timing and totality of this position liquidation warrant closer examination of management's forward outlook on the company's profitability trajectory.

CCO Maizel Ari sells entire 7.5K share position ($1.4M) of AXSM at $184.44; exits stake as stock rallies 43.5% in 90 days.

Maizel Ari, Chief Commercial Officer of Axsome Therapeutics, liquidated his entire 7,500 share holding for $1,383,300.00 on 2026-01-21 at $184.44 per share, reducing his position from 7,500 shares to 0 shares. The transaction occurred as AXSM stock has appreciated significantly—climbing 43.5% over the past 90 days and 21.0% over 30 days—leaving the sale price just 1.7% below the 52-week high of $189.10. The timing is notable given that the company remains unprofitable (net income of $-47,229,000.00 in its most recent full fiscal year) despite strong revenue growth of 42.5% year-over-year and a $9.4B market capitalization. A complete exit by a C-suite executive during a steep uptrend, particularly in an unprofitable firm, warrants investor attention to assess whether this reflects changes in company outlook, personal portfolio decisions, or other considerations affecting near-term prospects.